
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>American Gastroenterological Association Clinical Practice Guideline: <b>Surveillance of Barrett’s Esophagus</b></title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 1120px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 8px 0;
    padding: 20x 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: 8px;
    border-color: #a855f7;
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 15px;
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.9);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 0.95em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>American Gastroenterological Association Clinical Practice Guideline: <b>Surveillance of Barrett’s Esophagus</b></strong></summary>
            <div>
                <ul><li>Source: American Gastroenterological Association (AGA) Guideline Document.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>Test your knowledge before you begin:</li><li>1. What is the annual risk of progression to HGD/EAC in patients with short-segment BE (<3 cm)?</li><li>2. What is the pooled incidence of HGD/EAC in patients with columnar lined esophagus <1 cm with intestinal metaplasia?</li><li>3. What is the pooled rate of progression to HGD/EAC among NDBE patients with aberrant p53 expression?</li><li>4. What percentage of EACs are categorized as Post-Endoscopy Esophageal Adenocarcinoma (PEEC)?</li><li>5. What is the failure rate of anti-reflux surgery at 5 years?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Introduction & Health Problem</strong></summary>
            <div>
                <ul><li><b>Barrett’s Esophagus (BE)</b> is the only identifiable precursor to <b>Esophageal Adenocarcinoma (EAC)</b>.</li><li>EAC has a dismal 5-year survival rate of approximately <q><b>20%</b></q>.</li><li>BE progresses to EAC in a stepwise fashion: Low-Grade Dysplasia (LGD) ---> High-Grade Dysplasia (HGD) ---> Invasive EAC.</li></ul>
                
        <details>
            <summary><strong>Goal of Surveillance</strong></summary>
            <div>
                <ul><li><u>Primary Goal</u>: Early detection of BE-related neoplasia (dysplasia and early-stage cancer).</li><li><u>Secondary Goals</u>:</li><li>- Enable treatment with Endoscopic Eradication Therapy (EET).</li><li>- Reduce morbidity/mortality from esophagectomy.</li><li>- Ultimately prevent EAC mortality.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Surveillance in <b>Non-Dysplastic Barrett’s Esophagus (NDBE)</b></strong></summary>
            <div>
                <ul><li><b>Recommendation</b>: In patients with NDBE, the AGA <u>suggests</u> performing endoscopic surveillance compared to no surveillance.</li><li>(Conditional recommendation, low certainty).</li></ul>
                
        <details>
            <summary><strong>Evidence: <b>Benefits</b> of Surveillance</strong></summary>
            <div>
                <ul><li><u>EAC-Specific Mortality</u>: Surveillance is associated with a significant reduction.</li><li>- Pooled RR: <q><b>0.60</b></q> (95% CI 0.50, 0.71) from observational studies.</li><li>- Absolute risk reduction: <q><b>231 fewer deaths per 1,000</b></q>.</li><li><u>Overall Survival</u>: The BOSS trial (RCT) showed no significant difference.</li><li>- HR: <q><b>0.95</b></q> (95% CI 0.82, 1.10).</li><li><u>Early-Stage Disease Detection</u>: Surveillance significantly increases detection of early-stage EAC/HGD.</li><li>- BOSS Trial RR: <q><b>2.82</b></q> (95% CI 1.73, 4.56).</li><li>- Absolute difference: <q><b>21 more cases of early-stage EAC/HGD per 1,000</b></q>.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Evidence: <b>Harms</b> of Surveillance</strong></summary>
            <div>
                <ul><li>Serious adverse events from endoscopy are rare.</li><li>- Bleeding rate: <q><b>7.9 per 10,000</b></q> persons.</li><li>- Perforation rate: <q><b>0.4 per 10,000</b></q> individuals.</li><li>- 7-day infection rate: <q><b>30 per 10,000</b></q> individuals.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Discussion & Rationale</strong></summary>
            <div>
                <ul><li>The recommendation relies heavily on observational studies due to limitations of the BOSS trial.</li><li><u>BOSS Trial Limitations</u>:</li><li>- Likely underpowered for mortality outcomes.</li><li>- High rate of endoscopy (<q><b>59%</b></q>) in the 'at need' control arm, causing contamination.</li><li>- Nearly <q><b>25%</b></q> of patients lacked intestinal metaplasia, limiting generalizability.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Implementation: <b>Surveillance Intervals</b></strong></summary>
            <div>
                <ul><li>Suggested interval for NDBE is every <q><b>3 years</b></q> if a high-quality exam was performed.</li><li>Interval may be extended to every <q><b>5 years</b></q> in lower-risk patients (e.g., short-segment BE).</li></ul>
                
        <details>
            <summary><strong>Rationale for Intervals</strong></summary>
            <div>
                <ul><li>Based on modeling studies and cost-effectiveness analyses.</li><li>Optimal intervals in the U.S. are every <q><b>2 to 5 years</b></q> for NDBE.</li><li>Shorter intervals are suggested for men than women.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Post-Endoscopy Esophageal Neoplasia (PEEN/PEEC)</strong></summary>
            <div>
                <ul><li>High prevalence of missed dysplasia/cancer on index exams.</li><li>Pooled analysis reports PEEC of <q><b>17%</b></q> in patients diagnosed as NDBE on index exam.</li><li>If index exam quality is questionable, consider repeat endoscopy within 1 year.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Implementation: <b>Risk Stratification</b></strong></summary>
            <div>
                <ul><li>Surveillance intervals can be modified based on clinical risk factors.</li></ul>
                
        <details>
            <summary><strong>BE Length</strong></summary>
            <div>
                <ul><li>The risk factor with the greatest evidence.</li><li>Annual risk of progression to EAC is significantly lower for short-segment (<3 cm) vs. long-segment BE (<q><b>0.06% vs. 0.31%</b></q>).</li><li>Risk of HGD/EAC doubles for every <q><b>4 cm</b></q> increase in length.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Other Clinical Factors</strong></summary>
            <div>
                <ul><li><u>Smoking</u>: Associated with <q><b>~1.5x</b></q> greater odds of progressing.</li><li><u>Male Sex</u>: Associated with approximately <q><b>double the risk</b></q> of progressing.</li><li><u>Increasing BMI</u>: OR of <q><b>1.06</b></q> per 5 kg/m² increment.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Progression in Barrett’s Esophagus (PIB) Score</strong></summary>
            <div>
                <ul><li>Combines risk factors: Male sex (<q><b>9 points</b></q>), smoking (<q><b>5 points</b></q>), BE length (<q><b>1 point/cm</b></q>), confirmed LGD (<q><b>11 points</b></q>).</li><li>A low-risk score (<11 points) had an annual progression risk of <q><b>0.13% - 0.2%</b></q>.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Implementation: <b>Discontinuation of Surveillance</b></strong></summary>
            <div>
                <ul><li>Consider discontinuation based on age and medical comorbidities.</li><li>Optimal discontinuation age ranges from <q><b><65 to 83 years</b></q>, depending on sex and comorbidities.</li><li>Initiate conversation about discontinuation around age <q><b>75</b></q> in a healthy male.</li><li>ESGE recommends cessation at age <q><b>75</b></q> if no prior history of dysplasia.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Optimal Imaging Strategy: <b>Chromoendoscopy (CE)</b></strong></summary>
            <div>
                <ul><li><b>Recommendation</b>: In patients undergoing screening or surveillance, the AGA <u>recommends</u> using a combination of <b>high-definition white light endoscopy (HD-WLE) plus chromoendoscopy</b> compared to WLE alone.</li><li>(Strong recommendation, moderate quality of evidence).</li></ul>
                
        <details>
            <summary><strong>Evidence: <b>Benefits</b> of Chromoendoscopy</strong></summary>
            <div>
                <ul><li><u>Detection of HGD/EAC</u>: CE + WLE significantly increases detection.</li><li>- RR: <q><b>1.20</b></q> (95% CI 1.03-1.4).</li><li>- Absolute increase: <q><b>33 more cases per 1,000 patients</b></q>.</li><li><u>Detection of Any Dysplasia (LGD/HGD/EAC)</u>:</li><li>- RR: <q><b>1.16</b></q> (95% CI 1.07-1.27).</li><li>- Absolute increase: <q><b>61 more cases per 1,000 patients</b></q>.</li></ul>
                
        <details>
            <summary><strong>Subgroup Analysis (General Surveillance Population)</strong></summary>
            <div>
                <ul><li>Restricting analysis to studies reflecting a general BE surveillance population showed a stronger effect for HGD/EAC detection.</li><li>- RR for HGD/EAC detection: <q><b>1.55</b></q> (95% CI 1.05-2.29).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Evidence: <b>Harms</b> of Chromoendoscopy</strong></summary>
            <div>
                <ul><li>Generally well-tolerated with no significant adverse events reported in studies.</li><li>Theoretical concerns include allergic reactions to dyes and potential DNA damage from methylene blue.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Implementation Considerations</strong></summary>
            <div>
                <ul><li><u>Choice of Modality</u>: Virtual (e.g., NBI) or dye-based (e.g., acetic acid) CE should be based on endoscopist/center expertise.</li><li>- Both NBI and acetic acid CE meet acceptable performance thresholds for dysplasia detection.</li><li><u><b>Adjunct, Not Substitute</b></u>: CE-directed biopsies should be used as an <b>adjunct to</b>, not a substitute for, a structured biopsy protocol.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Future Directions: Artificial Intelligence (AI)</strong></summary>
            <div>
                <ul><li>AI platforms (CADe/CADx) are being assessed to target neoplastic areas for sampling.</li><li>One study showed a CADe system was superior to endoscopists in detecting neoplasia in images (<q><b>90% vs. 74%</b></q>) and videos (<q><b>91% vs. 67%</b></q>).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Core Principles of a <b>High-Quality Examination</b></strong></summary>
            <div>
                <ul><li>A meticulous, high-quality endoscopic exam is crucial for accurate staging and minimizing missed neoplasia.</li></ul>
                
        <details>
            <summary><strong>Structured Biopsy Protocol (<b>Seattle Protocol</b>)</strong></summary>
            <div>
                <ul><li><u>Recommendation</u>: All patients with suspected or established BE should be sampled using a structured biopsy protocol.</li><li><u>Protocol</u>: Includes <b>targeted biopsies</b> from any visible lesions AND random <b>4-quadrant biopsies</b> every <q><b>2 cm</b></q> (if no prior dysplasia) or every <q><b>1 cm</b></q> (if history of dysplasia).</li><li><u>Evidence</u>: Pooled data showed a higher dysplasia detection rate with Seattle protocol vs. non-protocolized biopsies (<q><b>19.1% vs. 2.6%</b></q>).</li></ul>
                
        <details>
            <summary><strong>Limitations & Adherence</strong></summary>
            <div>
                <ul><li>Adherence rates can be suboptimal, as low as <q><b>49%</b></q>.</li><li>Longer BE segments are associated with lower adherence, despite these patients benefiting most.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Intra-procedure Best Practices</strong></summary>
            <div>
                <ul><li><u>Mucosal Visualization</u>: Use distal cap, insufflation/desufflation, and mucosal cleansing.</li><li><u>Landmark Identification</u>: Accurately measure and document squamocolumnar junction, GEJ, and diaphragmatic hiatus.</li><li><u>Inspection Time</u>: Spend adequate time inspecting the BE segment. One study suggests <q><b>>1 minute per 1 cm</b></q> of Barrett's mucosa is associated with higher detection of suspicious lesions.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Standardized Documentation</strong></summary>
            <div>
                <ul><li><u><b>Prague C&M Classification</b></u>: To describe the circumferential (C) and maximal (M) extent of columnar mucosa.</li><li><u><b>Paris Classification</b></u>: To describe the macroscopic appearance of any visible superficial lesion.</li><li><u><b>Los Angeles (LA) Classification</b></u>: To grade and report erosive esophagitis.</li></ul>
                
        <details>
            <summary><strong>Handling Severe Esophagitis</strong></summary>
            <div>
                <ul><li>In the presence of active LA Grade C or D esophagitis, repeat surveillance endoscopy after <q><b>at least six weeks</b></q> of optimized anti-reflux therapy.</li><li>However, perform detailed inspection and targeted biopsies of any suspicious lesions even with severe esophagitis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management of <b>Dysplasia</b> & <b>Indefinite for Dysplasia (IND)</b></strong></summary>
            <div>
                <ul><li><u>Referral</u>: Patients with BE-related neoplasia (including LGD and IND) should be referred to <b>high-volume endoscopists</b> and <b>expert pathologists</b>.</li><li><u>Confirmation</u>: Histologic diagnosis of dysplasia or early cancer should be confirmed by an expert pathologist.</li></ul>
                
        <details>
            <summary><strong>Low-Grade Dysplasia (LGD)</strong></summary>
            <div>
                <ul><li><u>Confirmation</u>: Repeat upper endoscopy by an expert within <q><b>6 months</b></q> on high-dose acid suppressive therapy to rule out prevalent HGD/EAC.</li><li><u>Management Choice</u>: Shared decision-making between EET or continued surveillance.</li><li><u>Surveillance Plan (if chosen)</u>: Upper endoscopy at <q><b>6-month intervals for 1 year, then annually</b></q> by an expert endoscopist.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Indefinite for Dysplasia (IND)</strong></summary>
            <div>
                <ul><li><u>Progression Risk</u>: Pooled incidence of HGD/EAC is <q><b>1.5 per 100 person-years</b></q>.</li><li><u>Confirmation</u>: Repeat endoscopy on BID PPI therapy within <q><b>at least 3 months</b></q> with repeat sampling.</li><li><u>Management</u>: EET is <b>not recommended</b> for confirmed IND.</li><li><u>Surveillance Plan</u>: Undergo annual endoscopy until there is a change in histologic grade.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Adjunctive Sampling: <b>WATS-3D</b></strong></summary>
            <div>
                <ul><li><b>Recommendation</b>: The AGA makes <u>no recommendation</u> for or against the use of WATS-3D as an adjunctive sampling technique.</li><li>(Knowledge gap).</li></ul>
                
        <details>
            <summary><strong>Evidence: <b>Benefits</b> (Incremental Yield)</strong></summary>
            <div>
                <ul><li><u>HGD/EAC Detection</u>: WATS-3D + Seattle protocol vs. Seattle alone showed an increased detection.</li><li>- Overall RR: <q><b>1.61</b></q> (95% CI 1.25-2.08).</li><li>- In screening/surveillance populations, the effect was attenuated and not statistically significant (RR <q><b>1.35</b></q>).</li><li><u>Any Neoplasia Detection (LGD/HGD/EAC)</u>:</li><li>- Overall RR: <q><b>1.36</b></q> (95% CI 1.14-1.64).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Evidence: <b>Harms</b> & Concerns</strong></summary>
            <div>
                <ul><li>No major adverse events reported.</li><li><u>Primary Concern</u>: Downstream effects of potential <b>false positive</b> results, leading to unnecessary procedures or anxiety.</li><li>Longitudinal follow-up to confirm dysplasia found only on WATS-3D is limited.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Implementation Considerations</strong></summary>
            <div>
                <ul><li>WATS-3D should <b>not be used as a substitute</b> for a structured biopsy protocol.</li><li><u>Discordant Results</u>: If neoplasia is found on WATS-3D but not on biopsies, repeat endoscopy by an expert within <q><b>3-6 months</b></q>.</li><li><u>Crypt Dysplasia, IND, or LGD on WATS-3D only</u>: EET should <b>not</b> be performed.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Biomarkers for Risk Stratification</strong></summary>
            <div>
                <ul><li>Current standard is histologic grade of dysplasia, but it has limitations (sampling error, interobserver variability).</li><li>This section evaluates commercially available biomarkers.</li></ul>
                
        <details>
            <summary><strong><b>p53</b> Immunohistochemistry (IHC)</strong></summary>
            <div>
                <ul><li><b>Recommendation</b>: The AGA makes <u>no recommendation</u> for or against the routine use of p53 assessment.</li><li>(Knowledge gap).</li></ul>
                
        <details>
            <summary><strong>Evidence: <b>Predicting Progression</b></strong></summary>
            <div>
                <ul><li>Aberrant p53 expression is associated with a significantly higher risk of progression to HGD/EAC.</li><li>- Overall RR vs. normal p53: <q><b>10.17</b></q> (95% CI 6.89-15).</li><li>- NDBE with aberrant p53: Progression rate of <q><b>7 per 100 person-years</b></q> (vs. 0.5 without).</li><li>- LGD with aberrant p53: Progression rate of <q><b>11 per 100 person-years</b></q> (vs. 1 without).</li><li>- IND with aberrant p53: Progression rate of <q><b>6 per 100 person-years</b></q> (vs. 1 without).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Evidence: <b>Harms & Test Performance</b></strong></summary>
            <div>
                <ul><li><u>Overall Performance</u>: Suboptimal diagnostic characteristics.</li><li>- Pooled Sensitivity: <q><b>0.48</b></q></li><li>- Pooled Specificity: <q><b>0.85</b></q></li><li><u>Major Concern</u>: High number of <b>false positives (FP)</b>.</li><li>- For NDBE, for every 3 true positives, there were <q><b>149 false positives</b></q>.</li><li>- Calculated PPV was only <q><b>2%</b></q> for 1 year of follow-up.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong><b>TissueCypher</b> Testing</strong></summary>
            <div>
                <ul><li><b>Recommendation</b>: The AGA makes <u>no recommendation</u> for or against the routine use of TissueCypher testing.</li><li>(Knowledge gap).</li></ul>
                
        <details>
            <summary><strong>Evidence: <b>Predicting Progression</b> (NDBE)</strong></summary>
            <div>
                <ul><li><u>High-Risk vs. Intermediate/Low-Risk</u>:</li><li>- Sensitivity: <q><b>37%</b></q>, Specificity: <q><b>96%</b></q>, OR: <q><b>13.55</b></q>.</li><li><u>High/Intermediate-Risk vs. Low-Risk</u>:</li><li>- Sensitivity: <q><b>52%</b></q>, Specificity: <q><b>85%</b></q>, OR: <q><b>6.0</b></q>.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Evidence: <b>Harms & Test Performance</b> (NDBE)</strong></summary>
            <div>
                <ul><li>Using the high/intermediate vs. low-risk cutoff:</li><li>- For every 3 true positives, there were <q><b>149 false positives</b></q>.</li><li>- Calculated PPV was <q><b>2%</b></q> and NPV was <q><b>99.6%</b></q>.</li><li>Data for LGD and IND are very limited due to small sample sizes.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Chemoprevention Strategies</strong></summary>
            <div>
                <ul><li>Focuses on medical and behavioral interventions to prevent neoplastic progression.</li></ul>
                
        <details>
            <summary><strong><b>Proton Pump Inhibitor (PPI)</b> Therapy</strong></summary>
            <div>
                <ul><li><b>Recommendation</b>: In patients with BE, the AGA <u>suggests</u> the use of <b>daily PPI therapy</b> compared to no PPI therapy for prevention of neoplastic progression.</li><li>(Conditional recommendation, low quality of evidence).</li></ul>
                
        <details>
            <summary><strong>Evidence: <b>Benefits</b> of PPIs</strong></summary>
            <div>
                <ul><li><u>Progression to HGD/EAC</u>: Observational data shows a significant reduction in risk.</li><li>- Pooled OR: <q><b>0.47</b></q> (95% CI 0.32, 0.71).</li><li>- Absolute risk reduction: <q><b>84 fewer per 1,000</b></q>.</li><li><u>Indirect Evidence (AspECT Trial)</u>: Compared high-dose (BID) vs. low-dose (daily) PPI. No significant difference in progression to HGD/EAC (RR 0.84).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Evidence: <b>Harms</b> of PPIs</strong></summary>
            <div>
                <ul><li>RCT data (COMPASS trial) shows a small increased risk of enteric infections.</li><li>- OR for non-C. difficile enteric infections: <q><b>1.33</b></q> (95% CI 1.01, 1.75).</li><li>- Absolute risk: <q><b>4 more per 1,000</b></q>.</li><li>No statistically significant increase in C. difficile, CKD, dementia, pneumonia, or fracture in RCTs.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Aspirin & High-Dose PPI</strong></summary>
            <div>
                <ul><li>The AspECT trial showed a benefit for the combined endpoint of death, HGD, or EAC with high-dose PPI and aspirin.</li><li>However, there was no difference for the more relevant endpoint of HGD or EAC alone.</li><li>Therefore, <b>no recommendation</b> was made for aspirin or high-dose PPI therapy solely for chemoprevention.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Behavioral Modification</strong></summary>
            <div>
                <ul><li><u>Tobacco Cessation</u>: Smoking increases risk of BE progression (HR nearly double). Cessation should be encouraged.</li><li><u>Weight Loss</u>: Central adiposity is a risk factor. Increasing BMI is associated with increased risk of progression. Weight loss is appropriate for overweight/obese patients.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Role of <b>Anti-Reflux Surgery</b></strong></summary>
            <div>
                <ul><li><b>Recommendation</b>: In patients with BE, the AGA <u>suggests</u> the use of <b>proton pump inhibitors over surgery</b> for the prevention of neoplastic progression.</li><li>(Conditional recommendation, low quality of evidence).</li></ul>
                
        <details>
            <summary><strong>Evidence: <b>Benefits</b> of Surgery vs. Medical Management</strong></summary>
            <div>
                <ul><li><u>Progression to EAC</u>: No significant difference found in pooled analysis.</li><li>- RR: <q><b>1.33</b></q> (95% CI 0.29, 6.16).</li><li>- The largest cohort study showed surgery did <b>not</b> reduce EAC risk (adjusted HR <q><b>1.9</b></q>).</li><li><u>Progression to HGD/EAC</u>: No significant difference found.</li><li>- RR: <q><b>0.86</b></q> (95% CI 0.30, 2.41).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Evidence: <b>Harms</b> of Anti-Reflux Surgery</strong></summary>
            <div>
                <ul><li><u>Short-term Risks</u>:</li><li>- 30-day all-cause mortality rate: <q><b>0.1%</b></q>.</li><li>- Complication rate within 30 days: <q><b>4.1%</b></q> (includes infection, bleeding, esophageal perforation).</li><li><u>Long-term Issues</u>:</li><li>- Reflux recurrence: <q><b>17.7%</b></q>.</li><li>- Need for secondary anti-reflux surgery: <q><b>16.4%</b></q>.</li><li>- Failure rate at 5 years: <q><b>20-30%</b></q>.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Discussion & Rationale</strong></summary>
            <div>
                <ul><li>Existing evidence does not show consistent superiority of surgery over medical management for preventing progression.</li><li>Decision driven by the low risk of progression in NDBE, making it difficult to justify the risks associated with surgery.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Surveillance in <b>Columnar Lined Esophagus <1 cm</b></strong></summary>
            <div>
                <ul><li><b>Recommendation</b>: In patients with columnar lined esophagus <1 cm with intestinal metaplasia without neoplasia, the AGA <u>suggests against</u> endoscopic surveillance.</li><li>(Conditional recommendation, very low certainty of evidence).</li></ul>
                
        <details>
            <summary><strong>Evidence & Rationale</strong></summary>
            <div>
                <ul><li><u>Progression Risk</u>: The risk of progression to HGD/EAC is very low.</li><li>- Pooled incidence: <q><b>0.1 per 100 patient-years</b></q>.</li><li><u>Diagnostic Uncertainty</u>: The endoscopic diagnosis is fraught with substantial interobserver variability.</li><li><u>Resource Utilization</u>: Life-long surveillance in this large population offers little benefit and incurs costs, risks, and patient anxiety.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Implementation Considerations</strong></summary>
            <div>
                <ul><li>If the quality of the index exam is questionable, a <b>one-time repeat high-quality exam</b> can be performed to rule out prevalent neoplasia.</li><li>Shared decision-making is key; patients who place a high value on preventing EAC can reasonably choose a one-time repeat surveillance endoscopy.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong><b>Quality Indicators</b> in BE Surveillance</strong></summary>
            <div>
                <ul><li>Metrics to monitor and improve outcomes in patients with BE undergoing surveillance.</li></ul>
                
        <details>
            <summary><strong>Established Quality Measures</strong></summary>
            <div>
                <ul><li><u>Surveillance Intervals</u>: Adhering to appropriate intervals (e.g., no sooner than 3-5 years in NDBE).</li><li><u>Sampling Technique</u>: Appropriate use of the <b>Seattle biopsy protocol</b>.</li><li>- Studies show suboptimal adherence and wide variability for both measures.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Proposed Quality Metrics</strong></summary>
            <div>
                <ul><li><u>Neoplasia Detection Rate (NDR)</u>: Prevalence of HGD or EAC on index screening endoscopy.</li><li>- A meta-analysis proposed a threshold of <q><b>4%</b></q>.</li><li><u>Dysplasia Detection Rate (DDR)</u>: Prevalence of LGD or HGD during surveillance of NDBE.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Post-Endoscopy Esophageal Neoplasia (PEEN/PEEC)</strong></summary>
            <div>
                <ul><li><u>Definition</u>: HGD/EAC detected before the next recommended surveillance interval (between 6 months and 3 years after an index endoscopy negative for HGD/EAC).</li><li><u>Magnitude</u>: A SR/MA reported that PEEC accounted for <q><b>21%</b></q> of all EACs, and PEEN accounted for <q><b>26%</b></q> of all HGD/EAC cases.</li><li><u>Implication</u>: Suggests a high rate of missed neoplasia and an opportunity for quality improvement.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
